Therapeutics development

The standard four week delivery serves as a deliberate hallmark of scientific thoroughness that distinguishes our laboratory from high speed generalists. This timeframe allows our Zurich based experts to perform meticulous quality checks and individual cloning optimizations that automated standard procedures often overlook. Saving ten days in the discovery phase represents a net loss if a lack of thoroughness leads to developability issues or failure during critical scale up milestones.

Chinese Hamster Ovary cells represent the industry standard for manufacturing therapeutic antibodies and utilizing them from day one ensures that early discovery data remains directly relevant to clinical scale production. By eliminating the host cell variable, we prevent the “Translation Trap” where candidates optimized in HEK293 cells aggregate or fail when transitioned to CHO for manufacturing. This approach de risks the entire journey from the bench to the clinic by ensuring that the molecule screened is the molecule scaled.

Standardized robotics assisted CHO processes provide the clean training data required for predictive success in machine learning and antibody engineering. For organizations leveraging AI, the quality of the training set remains the most critical factor, so we ensure the sequence is the only variable in the expression process. By providing the cleanest possible experimental material, we ensure that digital models are trained on reliable data that is truly predictive of manufacturing success.

Our laboratory acts as a bespoke forge for challenging constructs including bispecifics and trispecifics or fusion proteins that often fail in rigid and menu driven workflows. We have produced over 25,000 antibody based molecules and consistently achieve greater than 95 percent correct pairing for complex formats such as Knobs into Holes or CrossMab. This specialization allows our partners to manage difficult structural liabilities with absolute scientific flexibility.

Absolute scientific flexibility remains the cornerstone of our partnership model because we understand that therapeutic development rarely follows a linear path. Unlike rigid providers who enforce fixed menus or predefined packages, we individually discuss and design every expression strategy to match specific preclinical objectives. This approach allows us to pivot alongside your research needs and accommodate custom optimization requests that standard high throughput platforms cannot support.

Strategic engineering options including GlymaxX for afucosylation and mAbsolve STR for Fc silencing are fully integrated into our CHO platform to optimize antibody function early in development. By incorporating these advanced technologies during the discovery phase, researchers can generate material that is already optimized for enhanced potency or reduced side effect profiles. This proactive integration provides a significant head start on developability and ensures that lead candidates are functionally superior before they reach the manufacturing stage.

Absolute flexibility across all stages of development allows us to provide scales ranging from 0.1 mg for initial screenings to 10 g for advanced in vivo studies and IND enabling work. Every project maintains a guaranteed purity of greater than 95 percent and endotoxin levels below 1 EU per mg as a standard to support the most sensitive biological assays. This consistency ensures that the data foundation remains stable as lead candidates advance through the pipeline.

Recombinant antibody production at evitria is 100 percent cell based and animal free to align with modern ethical standards and global regulatory trends. This commitment ensures a higher level of process control and consistency while meeting the zero tolerance requirements of government organizations and global pharmaceutical corporations. By removing animal derived components from the production chain, we provide a robust and traceable platform for all research applications.

Highly optimized and standardized protocols ensure that every production run remains reproducible across multiple years of a development program. We maintain detailed process documentation and utilize comprehensive analytics such as LC MS analysis to demonstrate consistency across multiple productions. This level of precision provides the decision grade data required for publications and grant applications as well as therapeutic advancement.

Services are strictly limited to the research and preclinical stages of drug discovery and our products are not for human use. The mission of evitria is to ensure that the transition of a molecule from the bench to preclinical validation is successful so that it possesses a viable path toward clinical development handled by the client. We focus exclusively on providing the high quality material required to move a candidate forward with absolute confidence.